AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1671631
Drug: Sulphasalazine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine plus prednisone (6 g/d sulphasalazine, 30 mg/d prednisone initially, tapered to 10 mg/d after 8 weeks)
Trial: 1671631
Drug: Sulphasalazine alone
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulphasalazine alone (6 g/d, placebo for prednisone)
Trial: 29100262
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (cold drink + dexamethasone)
Trial: 22322141
Drug: Biobrane® and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biobrane® and autologous cell suspension using the ReCell® kit
Trial: 22322141
Drug: Local standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local standard treatment (Intrasite™, Acticoat™, and Duoderm(®) dressings every 2‐3 days) with surgery at 10 days
Trial: 16170293
Drug: Metoclopramide infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide infusion supplemented by vitamin B12 complex
Trial: 12826840
Drug: 6% HES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% HES 130/0.4 at a dose of up to 50 ml/kg
Trial: 12826840
Drug: 6% HES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% HES 200/0.5 at a dose of up to 33 ml/kg
Trial: 8938603
Drug: Pharmacological agents
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological agents designed to augment functional recovery of the injured spinal cord
Trial: 8938603
Drug: New drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New drugs evaluated through scientific and regulatory processes
Trial: 8938603
Drug: Classification scheme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classification scheme based on FDA regulations for drug availability
Trial: 1510257
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (3 mL)
Trial: 1510257
Drug: 1.5% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% lidocaine with epinephrine 1:200,000 (1 mL, diluted to 3 mL with normal saline)
Trial: 1510257
Drug: 1.5% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% lidocaine with epinephrine 1:200,000 (2 mL, diluted to 3 mL with normal saline)
Trial: 1510257
Drug: 1.5% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% lidocaine with epinephrine 1:200,000 (3 mL, diluted to 3 mL with normal saline)
Trial: 30015544
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (BLT) with light glasses for 4 weeks
Trial: 30015544
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (BLT) for 4 weeks
Trial: 22829023
Drug: Telmisartan alone
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan alone or in combination with Ramipril
Trial: 19102753
Drug: GINA guidelines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GINA guidelines treatment for 2 months
Trial: 10588075
Drug: Baseline variables
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline variables (age and treatment assignment adjusted)
Trial: 7496757
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen administered every 8 hours for 1-hour duration for a 2-week period
Trial: 31831868
Drug: Saroglitazar 4
RxNorm normalized name: Saroglitazar 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saroglitazar 4 mg daily for 4 months
Trial: 28295959
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg/d (first exposure)
Trial: 28295959
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg/d (second exposure)
Trial: 28295959
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg/d (first and second exposure correlation)
Trial: 26695794
Drug: Different drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different drug therapies for type A (acute sensorineural hearing loss in low tone frequencies)
Trial: 26695794
Drug: Different drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different drug therapies for type C (acute sensorineural hearing loss in all frequencies)
Trial: 26695794
Drug: Different drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different drug therapies for type B (acute sensorineural hearing loss in high tone frequencies)
Trial: 26695794
Drug: Different drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different drug therapies for type D (total deafness)
Trial: 26695794
Drug: Overall comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall comparison of four different treatment groups
Trial: 17298707
Drug: SYN1 (spray‐dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYN1 (spray‐dried mixture of chicory oligofructose and long‐chain inulin)
Trial: 9514453
Drug: Atorvastatin, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin, 80 mg/day
Trial: 7698708
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 x 0.9% saline solution subcutaneously)
Trial: 335793
Drug: s.c. heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. heparin alone
Trial: 335793
Drug: s.c. heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. heparin + p.o. acenocoumarin
Trial: 335793
Drug: s.c. heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. heparin (5000 IU twice daily)
Trial: 25833163
Drug: Hib-MenAC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib-MenAC vaccine (administered in 2-dose series for 6-23 months and single dose for 2-5 years)
Trial: 25833163
Drug: Licensed vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed vaccines (control group)
Trial: 22056152
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) and radiation therapy (RT) (65‐69 Gy to the prostate and seminal vesicles, 45 Gy to the pelvic nodes)
Trial: 7130340
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose estrogen (1/0.5 mg)
Trial: 7130340
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose estrogen (2/1 mg)
Trial: 7130340
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose estrogen (4/2 mg)
Trial: 7130340
Drug: All hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All hormone groups (low, medium, high)
Trial: 7130340
Drug: Post-treatment values
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment values of S-aPh and U-HyPro
Trial: 28214948
Drug: Fiix-warfarin patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiix-warfarin patients
Trial: 28214948
Drug: PT-warfarin patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT-warfarin patients
Trial: 24676313
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day of Zn for 6 months
Trial: 24676313
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day of Zn for 6 months
Trial: 22554019
Drug: 3.5% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5% lidocaine gel
Trial: 17920374
Drug: Intravenous esmolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esmolol (beta(1) blockade)
Trial: 16135174
Drug: Adjustable dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustable dose regimen
Trial: 11755936
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg per oral)
Trial: 2913252
Drug: Topical tetracycline
RxNorm normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracycline used as a suspension in a gelatin sponge placed in the sockets of extracted mandibular third molars.
Trial: 1093426
Drug: Intramuscular diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular diazepam 10 mg
Trial: 1093426
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral and intramuscular diazepam
Trial: 23560884
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl (2 μg/kg)
Trial: 23560884
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (2 μg/kg)
Trial: 12512928
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg oral misoprostol every 3 hours
Trial: 12512928
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg oral misoprostol every 6 hours
Trial: 10335039
Drug: rhGH (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (recombinant human growth hormone) administered daily subcutaneously for 12 months, initial dose 0.125 IU/kg b.w./week, adjusted to maintain serum IGF-1 levels of 280-350 micrograms/L.
Trial: 4569549
Drug: Oxytocin (Syntocinon)
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin (Syntocinon) administered in escalating doses
Trial: 11392598
Drug: Oxytocin (by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (by intravenous infusion)
Trial: 20399212
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone (200 mg)
Trial: 17654043
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of l-arginine and 75 mg of acetylsalicylic acid daily for 20 days
Trial: 11796357
Drug: Caspofungin (35,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (35, 50, or 70 mg)
Trial: 11796357
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (0.5 mg/kg)
Trial: 11796357
Drug: Caspofungin (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (any dose)
Trial: 184912
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation therapy (RT) added to 15 months' maintenance actinomycin D (AMD) in Gp I patients under 2 years of age
Trial: 30939487
Drug: COLM‐SST (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COLM‐SST (25 mg of caraway oil and 20.75 mg of L‐menthol per capsule, at 2 capsules per dose, twice per day)
Trial: 28577848
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cryothermal and bipolar radiofrequency (group 2)
Trial: 20805005
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (400 mcg/d) + vitamin B12 (100 mcg/d) supplementation
Trial: 16525137
Drug: Entecavir 0.5
RxNorm normalized name: entecavir 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 0.5 mg once daily for 52 weeks
Trial: 10809816
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) in combination with cyclosporin and prednisone (MMF+)
Trial: 8852484
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (3 g/day with triglyceride preparation; 7.7 g/day with ethyl-ester preparation)
Trial: 6391667
Drug: Antacid given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid given seven times a day combined with 600 mg BID of cimetidine (C + A7)
Trial: 6391667
Drug: Antacid given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid given four times a day combined with cimetidine BID (C + A4)
Trial: 6391667
Drug: Antacid alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid alone seven times daily (A7)
Trial: 6391667
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active treatments (C + A7, C + A4, A7) compared to placebo
Trial: 6391667
Drug: Cimetidine morning
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine morning dose
Trial: 6391667
Drug: Cimetidine coadministration
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine coadministration with antacid
Trial: 31633760
Drug: Pediatric-specific tumescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric-specific tumescent vasopressor solution and vasopressor-soaked topical compresses
Trial: 22184058
Drug: Urinary cotinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary cotinine >1.3 ng ml(‐1)
Trial: 17548089
Drug: Tibolone (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (1.25 or 2.5 mg/d)
Trial: 10505303
Drug: Hepatitis C
RxNorm normalized name: hepatitis C virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis C virus (HCV) antibody
Trial: 10505303
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B core antibody (HBcAb)
Trial: 7039282
Drug: Lorcainide, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcainide, 100 mg twice daily
Trial: 27043946
Drug: Continuous application
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous application of local anaesthetic through subcutaneous catheter
Trial: 25780881
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic Acid (AA) 100 mg/kg infusion 6 hours before donor operation and subsequent infusion of 100 mg/kg every 6 hours until organ removal
Trial: 23851059
Drug: Adaptive cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive cardiac resynchronization therapy (aCRT) with synchronized left ventricular pacing (sLVP)
Trial: 18727647
Drug: Drug and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug and behavioural therapy for acute headache treatment
Trial: 18727647
Drug: Invasive procedures
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Invasive procedures (injections)
Trial: 8039526
Drug: Oral drugs
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drugs
Trial: 16834790
Drug: High volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High volume (60 mL of anaesthetic solution)
Trial: 16834790
Drug: Low volume
RxNorm normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low volume (30 mL of anaesthetic solution)
Trial: 9199943
Drug: Bamiphylline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bamiphylline (300 mg)
Trial: 1287196
Drug: Two prototypical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two prototypical ethanol-water flux-enhanced transdermal therapeutic systems
Trial: 4005127
Drug: Oros system
RxNorm normalized name: Oro Clense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oros system with initial release rate of 14 mg/h
Trial: 4005127
Drug: Oros system
RxNorm normalized name: Oro Clense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oros system with initial release rate of 19 mg/h
Trial: 3589362
Drug: Gestagen therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestagen therapy (lynestrenol)
Trial: 26962903
Drug: Trimethoprim-sulfamethoxazole (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (320 mg and 1600 mg, respectively, twice daily for 7 days)
Trial: 20858114
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg triamcinolone acetonide monotherapy (n=17)
Trial: 20858114
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg bevacizumab monotherapy (n=14)
Trial: 20858114
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2 mg triamcinolone acetonide and 1.25 mg bevacizumab (n=21)
Trial: 15931282
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (60 mg/day elemental iron)
Trial: 3036259
Drug: m-chlorophenylpiperazine (m-CPP)
RxNorm normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-chlorophenylpiperazine (m-CPP) 0.5 mg/kg
Trial: 8096880
Drug: Oxitropium bromide
RxNorm normalized name: oxitropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxitropium bromide 0.2 mg
Trial: 2879736
Drug: Loratadine (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (160 mg)
Trial: 2879736
Drug: Chlorpheniramine maleate
RxNorm normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine maleate (4 mg)
Trial: 22998983
Drug: Individual Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Cognitive Stimulation Therapy (iCST) sessions delivered by a carer for 30 minutes, 3 times a week over 25 weeks
Trial: 11810078
Drug: 20-cm² patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-cm² patch (Ortho Evra)
Trial: 11810078
Drug: All patch
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patch regimens
Trial: 1283730
Drug: IGF-I (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF-I (40 micrograms/kg by single subcutaneous dose)
Trial: 30043192
Drug: Home-based sensory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based sensory interventions plus standard therapy
Trial: 30043192
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (speech therapy and applied behavior analysis)
Trial: 22964975
Drug: Pioglitazone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15 mg/day) for 12 weeks
Trial: 22097160
Drug: Multi-drug injection
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-drug injection (ropivacaine, morphine, ketorolac, and epinephrine)
Trial: 22097160
Drug: Multi-drug injection
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-drug injection
Trial: 10966889
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (providing 2.0 g EPA/d and 1.4 g DHA/d)
Trial: 10966889
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil (providing 12.3 g oleate/d)
Trial: 10966889
Drug: Safflower oil
RxNorm normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower oil (providing 10.5 g linoleate/d)
Trial: 9201636
Drug: Static stretch
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static stretch (30 seconds, twice daily)
Trial: 9201636
Drug: Active stretch
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active stretch (30 repetitions of active knee extension while sitting in a neural slump position, twice daily)
Trial: 30019970
Drug: 755-nm picosecond
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 755-nm picosecond pulsed alexandrite laser treatments (4 treatments, spaced 3 weeks apart)
Trial: 30019970
Drug: 1927-nm fractionated
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1927-nm fractionated thulium laser treatments (2 treatments, spaced 6 weeks apart)
Trial: 24283160
Drug: Red clover
RxNorm normalized name: Red clover
DrugBank: Trifolium pratense pollen (DB15530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red clover isoflavones supplementation (60.8 mg red clover isoflavones plus 19.2 mg soy isoflavones)
Trial: 21596867
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL of autologous blood
Trial: 21596867
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of autologous blood
Trial: 21596867
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of autologous blood